DRUG-METABOLIZING-ENZYMES RELATED TO LABORATORY MEDICINE - CYTOCHROMES P-450 AND UDP-GLUCURONOSYLTRANSFERASES

被引:24
作者
BATT, AM
MAGDALOU, J
VINCENTVIRY, M
OUZZINE, M
FOURNELGIGLEUX, S
GALTEAU, MM
SIEST, G
机构
[1] CTR MED,CNRS,URA 597,F-54000 NANCY,FRANCE
[2] CTR MED PREVENT,F-54501 VANDOEUVRE NANCY,FRANCE
关键词
CYTOCHROMES P-450; UDP-GLUCURONOSYLTRANSFERASES; PHENOTYPES; GENOTYPES;
D O I
10.1016/0009-8981(94)90214-3
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Many studies on drug metabolism have been carried out during the last decades using protein purification, molecular cloning techniques and analysis of polymorphisms at phenotype and genotype levels. These researches led to a better understanding of the role of drug metabolizing enzymes in the biotransformation of drugs, pollutants or foreign compounds and of their use in laboratory medicine. The metabolic processes commonly involved in the biotransformation of xenobiotics have been classified into functionalization reaction (phase I reactions), which implicate lipophilic compounds. These molecules are modified via monooxygenation, dealkylation, reduction, aromatization, hydrolysis and can be substrates for the phase II reactions, often called conjugation reactions as they conjugate a functional group with a polar, endogenous compound. This review, devoted to cytochromes P-450 (CYP) and UDP-glucuronosyltransferases (UGT), describes essentially the genetic polymorphisms found in humans, their clinical consequences and the methods to assess the phenotypes or genotypes, with a view to studying the interindividual differences in drug monooxygenation and drug glucuronidation. Variations in drug glucuronidation reported here focused essentially on variations due to physiological factors, induction, drug interactions and genetic factors in disorders such as Gilbert's Syndrome and Crigler-Najjar type I and II diseases.
引用
收藏
页码:171 / 190
页数:20
相关论文
共 111 条
[41]   GENOTYPING OF POOR METABOLIZERS OF DEBRISOQUINE BY ALLELE-SPECIFIC PCR AMPLIFICATION [J].
HEIM, M ;
MEYER, UA .
LANCET, 1990, 336 (8714) :529-532
[42]   EVOLUTION OF A HIGHLY POLYMORPHIC HUMAN CYTOCHROME P450 GENE-CLUSTER - CYP2D6 [J].
HEIM, MH ;
MEYER, UA .
GENOMICS, 1992, 14 (01) :49-58
[43]   GLUCURONIDATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE IN HUMAN LIVER-MICROSOMES - ENZYME-INHIBITION BY DRUGS AND STEROID-HORMONES [J].
HERBER, R ;
MAGDALOU, J ;
HAUMONT, M ;
BIDAULT, R ;
VANES, H ;
SIEST, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1139 (1-2) :20-24
[44]  
HERD B, 1991, BRIT J CLIN PHARMACO, V32, P768
[45]   THE HUMAN CYP2E1 GENE AND LUNG-CANCER - DRAI AND RSAI RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS IN A FINNISH STUDY POPULATION [J].
HIRVONEN, A ;
HUSGAFVELPURSIAINEN, K ;
ANTTILA, S ;
KARJALAINEN, A ;
VAINIO, H .
CARCINOGENESIS, 1993, 14 (01) :85-88
[46]  
IYANAGI T, 1989, J BIOL CHEM, V264, P21302
[47]  
IYANAGI T, 1988, CELLULAR MOL ASPECTS, V173, P3
[48]  
JACKSON MR, 1988, MOL PHARMACOL, V34, P638
[49]   PHENOTYPING POLYMORPHIC DRUG-METABOLISM IN THE FRENCH CAUCASIAN POPULATION [J].
JACQZ, E ;
DULAC, H ;
MATHIEU, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (02) :167-171
[50]  
KATO S, 1992, CANCER RES, V52, P6712